

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

### **Certification of Compliance**

## Under 42 U.S.C. § 282(j)(5)(B), with Requirements of ClinicalTrials.gov Data Bank

(For submission with an application/submission, including amendments, supplements, and resubmissions, under §§ 505, 515, 520(m), or 510(k) of the Federal Food, Drug, and Cosmetic Act or § 351 of the Public Health Service Act.)

SPON	ISOR / APPLICANT / SUBMITTER	RINFORMATION
1. Name of Sponsor/Applicant/Submitter	2. Date of the Application/Submission	
ModernaTx, Inc	09/21/2021	
3. Address		4. Telephone and Fax Numbers
Address 1 (Street address, P.O. box, company 200 Technology Square	(Include country code if applicable and area code)	
Address 2 (Apartment, suite, unit, building, floor, etc.)		(Tel): <u>617-803-1357</u>
City Cambridge	State/Province/Region MA	(Fax):
Country United States	ZIP or Postal Code 02139	
		)N
Spikevax mRNA-1273 Moderna COVID-19 Vaccine		roprietary or Model Name(s) and/or Model Number(s)
Δ	Continuation Page for #	
6. Type of Application/Submission Which This Cer		
	BLA PMA HDE	510(k) PDP Other
7. Include IND/NDA/ANDA/BLA/PMA/HDE/510(k)/ (If number previously assigned) 125752	PDP/ Other Number If E	3LA was selected in item 6, provide Supplement Number
8. Serial Number Assigned to Application/Submiss 00005	sion Which This Certification Accompa	anies
С	ERTIFICATION STATEMENT / INI	FORMATION
9. Check only one of the following boxes (See inst		
	• • • • •	blic Health Service Act, including 42 CFR part 11, do not ies does not reference any clinical trial.
B. I certify that the requirements of 42 U. apply to any clinical trial referenced in		blic Health Service Act, including 42 CFR part 11, do not certification accompanies.
	mission which this certification accom	blic Health Service Act, apply to one or more of the clinical apanies and that the requirements of 42 U.S.C. 282(j),
	Certit	fication Statement / Information section continued on page 2

CERTIFICATION STATEMENT / INFORMATION (Continued)							
10. If you checked box C, in number 9, provide the National Clinical Trial (NCT) Number(s) for any "applicable clinical trial(s)," for which you (the sponsor/applicant/submitter) are the "responsible party" under 42 U.S.C. § 282(j)(1)(a)(i), section 402(j)(1)(a)(i) of the Public Health Service Act referenced in the application/ submission which this Certification accompanies. (Add continuation page as necessary.)							
NCT Number(s): NCT04283461 NCT	04405076	NCT04470427	NCT04649151	NCT04796896			
				Continuation Page for #10			
The undersigned declares, to the best of her/his I understand that the failure to submit the certific Service Act, and the knowing submission of a fail 301 of the Federal Food, Drug, and Cosmetic Act <b>Warning:</b> A willfully and knowingly	cation required by se certification un t.	42 U.S.C. § 282( der such section a	j)(5)(B), section 402(j)( re prohibited acts unde	(5)(B) of the Public Health r 21 U.S.C. § 331, section			
11. Name and Title of the Person who Signs Number 1	5	1					
Name		Title					
Michelle Olsen	ichelle Olsen Asso		Associate Director Global Regulatory Affairs				
12. Address         Address 1 (Street address, P.O. box, company name c/o)         200 Technology Square         Address 2 (Apartment, suite, unit, building, floor, etc.)			13. Telephone ar (Include coun area code) (Tel): <u>617-417</u>	try code if applicable and			
-	State/Province/Region		(Fax):				
Country United States		ZIP or Postal Code 02139					
14. Date of Certification 09/20/2021		15. Signature of Sponsor/Applicant/Submitter or an Authorized Representative (Sign) Sign Michelle Olsen Date: 2021.09.20 18:05:51 -04'00'					

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### \*\*\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*\*\*

The burden time for this collection of information is estimated to average 15 minutes and 45 minutes (depending on the type of application/ submission) per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# CONTINUATION PAGE FOR ITEM 10 – NCT Number(s)

If you have additional NCT Number(s) to enter, use as many of the provided slots below as needed.

NCT Number(s):	NCT04860297	· · ·					
nor number(s).							
	NCT04927065						
Remove Continuation Page Return to Form							

FORM FDA 3674 (4/18)